Run time: 59m

  0      0

2020 AABB Annual Meeting On-Demand

AM20-03: iPSCs for the Treatment of Beta Hemoglobinopathies

Oct 3, 2020 10:00am ‐ Oct 3, 2020 11:00am

Expiration Date: Dec 31, 2022

Credits: None available.

Standard: $25.00
Members: $20.00


Presented in collaboration with Be The Match BioTherapies®

Induced pluripotent stem cells (iPSCs), derived from adult cells, have the potential to form any cell type in the body. iPSCs are promising research tools for studying human development, modeling disease and potentially treating patients. Hemoglobinopathies such as sickle cell disease (SCD) and beta thalassemia (BT) are treated with a limited number of pharmacologic options and blood transfusions. The only curative treatment modality is allogeneic transplantation and autologous transplantation with hematopoietic progenitor cell (HPC)-based gene therapy but these approaches have limitations and the latter is still in clinical trials. HPC-based approaches require obtaining sufficient numbers of HPCs via a bone marrow harvest or peripheral blood stem cell collection and maintaining the HPCs ex vivo for more than a short period of time for ex vivo manipulation without a loss of engraftment ability which are challenging to do. iPSCs may offer potential benefits over HPC-based approaches. This session will provide information on the current state of iPSCs for the treatment of hemoglobinopathies.

Learning Objectives:
  • Discuss the role of iPSCs for drug screening and disease modeling
  • Discuss erythroid cell generation from iPSCs obtained from individuals without hemoglobinopathies and their potential clinical applications
  • Discuss cell and gene therapy for beta hemoglobinopathies with iPSCs



  • Eric Bouhassira, PhD : Nothing to disclose
  • Selami Demirci, PhD : Nothing to disclose
  • George Murphy, PhD : Nothing to disclose

Credits Available

AM20-03: iPSCs for the Treatment of Beta Hemoglobinopathies Evaluation

You must be logged in and own this session in order to post comments.